1 citations
,
January 2013 in “MedChemComm” PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
July 2025 in “Jurnal Farmasi Sains dan Praktis” Most adverse reactions to the treatment were mild, with nausea being the most common.
2 citations
,
January 2013 in “Iraqi journal of Medical Sciences” March 2026 in “British Journal of Dermatology” March 2013 in “The Journal of Urology” Non-daily Dutasteride is more cost-effective and has lower cancer incidence than daily treatment.
August 2025 in “Skin Appendage Disorders” Low-dose oral minoxidil might help with hair loss during chemotherapy, but more research is needed.
January 2017 in “Revista da Universidade Vale do Rio Verde” Finasteride is commonly used for male pattern hair loss but has potential risks, including irreversible sexual dysfunction.
August 2021 in “Skin appendage disorders” Two people lost hair unexpectedly after getting a common hair loss treatment with a drug called Dutasteride.
September 2025 in “PubMed” Prevent persistent hair loss after chemotherapy with scalp cooling and early minoxidil use.
1 citations
,
April 2025 in “Drug Delivery and Translational Research”
1 citations
,
September 2024 in “International Journal of Advanced Multidisciplinary Research and Studies” Chemotherapy with carboplatin-paclitaxel causes hair loss in all patients.
10 citations
,
March 2008 in “DMW - Deutsche Medizinische Wochenschrift” Estrogen treatments can cause unwanted effects in men and should be used cautiously.
42 citations
,
September 2020 in “American Journal of Clinical Dermatology” 8 citations
,
June 2023 in “European Journal of Endocrinology” The inhibitor affects androgen metabolism but not ovarian function.
Baricitinib helped treat a man's beard hair loss when steroids didn't work.
May 2015 in “Cancer research” After chemotherapy for early breast cancer, 33.4% of patients had long-term significant hair loss, with some hair regrowth over time, but treatments for hair loss were largely ineffective.
234 citations
,
September 2004 in “Clinical cancer research” BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
January 2004 in “Online Publication Service of Würzburg University (Würzburg University)” Women with PCOS have higher 5alpha-reductase activity, affecting steroid levels.
9 citations
,
April 2021 in “Expert opinion on pharmacotherapy” Clascoterone is a new, effective, and safe acne treatment without systemic side effects.
7 citations
,
March 2025 in “Cytotechnology”
July 2025 in “SKIN The Journal of Cutaneous Medicine” Oral minoxidil can help regrow hair lost from antibody-drug conjugate treatment.
1 citations
,
September 2020 in “Endocrinology, Diabetes & Metabolism Case Reports” The conclusion is that thorough investigation of hypertension and hormonal dysfunctions is important, and there may be a link between these conditions and cancer.
5 citations
,
January 2022 in “Clinical cancer investigation journal” Certain Dibenzo derivatives may help treat prostate cancer.
3 citations
,
May 2025 in “Frontiers in Pharmacology” Vismodegib can cause muscle spasms, taste changes, hair loss, fatigue, weight loss, and possibly new issues like skin cancer, dehydration, and swallowing problems, needing close monitoring.
75 citations
,
June 2019 in “International Journal of Molecular Sciences” Costunolide may have multiple health benefits, including promoting hair growth and protecting against cancer and diabetes, but more research is needed.
December 2025 in “npj Breast Cancer” Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.
4 citations
,
February 2019 in “PubMed” Clascoterone may be an effective topical treatment for hair loss.
17 citations
,
June 1996 in “The Journal of Steroid Biochemistry and Molecular Biology” FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.
8 citations
,
June 2022 in “Cancers” Epirubicin and cyclophosphamide cause more anemia and side effects than docetaxel and cyclophosphamide, but both are equally effective.